Vistin Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Vistin Pharma ha un patrimonio netto totale di NOK310.7M e un debito totale di NOK5.6M, che porta il suo rapporto debito/patrimonio netto a 1.8%. Le sue attività totali e le sue passività totali sono rispettivamente NOK387.9M e NOK77.2M. L'EBIT di Vistin Pharma è NOK82.7M rendendo il suo rapporto di copertura degli interessi -20.1. Ha liquidità e investimenti a breve termine pari a NOK5.6M.

Informazioni chiave

1.8%

Rapporto debito/patrimonio netto

NOK 5.64m

Debito

Indice di copertura degli interessi	-20.1x
Contanti	NOK 5.63m
Patrimonio netto	NOK 310.74m
Totale passività	NOK 77.21m
Totale attività	NOK 387.94m

Aggiornamenti recenti sulla salute finanziaria

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Feb 23

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Feb 20

Recent updates

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

Jan 29

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

Jan 08

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Dec 16

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Nov 26

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NOK143.8M ) di VISTN superano le sue passività a breve termine ( NOK67.4M ).

Passività a lungo termine: Le attività a breve termine di VISTN ( NOK143.8M ) superano le sue passività a lungo termine ( NOK9.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 0% ) di VISTN è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di VISTN è aumentato da 0% a 1.8% negli ultimi 5 anni.

Copertura del debito: Il debito di VISTN è ben coperto dal flusso di cassa operativo ( 1770% ).

Copertura degli interessi: VISTN matura più interessi di quanti ne paga, quindi la copertura dei pagamenti degli interessi non è un problema.

Vistin Pharma Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

Recent updates

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: kr0.37 (vs kr0.53 in 3Q 2023)

Upcoming dividend of kr0.50 per share

Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors

Now 21% undervalued

Second quarter 2024 earnings released: EPS: kr0.43 (vs kr0.16 in 2Q 2023)

Upcoming dividend of kr0.50 per share

Vistin Pharma ASA Approves Ordinary Dividend

First quarter 2024 earnings released: EPS: kr0.17 (vs kr0.067 loss in 1Q 2023)

Vistin Pharma ASA (OB:VISTN) acquired 15% stake in CF Pharma Ltd. for €1.6 million.

Full year 2023 earnings released: EPS: kr1.03 (vs kr0.11 loss in FY 2022)

Vistin Pharma ASA Proposes an Ordinary Dividend for the Accounting Year of 2023, Payable on or About 18 June 2024 and 19 November 2024

Upcoming dividend of kr0.75 per share at 3.1% yield

Vistin Pharma ASA Announces Cash Dividend, Payable on or About 30 January 2024

Vistin Pharma ASA Announces Cash Dividend, Payable on or About 30 January 2024

Vistin Pharma ASA, Annual General Meeting, May 23, 2024

Third quarter 2023 earnings released: EPS: kr0.53 (vs kr0.15 loss in 3Q 2022)

Vistin Pharma ASA Appoints Magnus Tolleshaug as the New CEO From, 1 January 2024

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.005 in 2Q 2022)

Interim CEO recently bought kr360k worth of stock

First quarter 2023 earnings released: kr0.067 loss per share (vs kr0.34 loss in 1Q 2022)

Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?

Full year 2022 earnings released: kr0.11 loss per share (vs kr0.56 profit in FY 2021)

Vistin Pharma ASA to Report Q3, 2023 Results on Oct 26, 2023

Less than half of directors are independent

Third quarter 2022 earnings released: kr0.15 loss per share (vs kr0.021 profit in 3Q 2021)

Vistin Pharma ASA Provides Production Guidance for the Fourth Quarter and Year 2022

Now 24% undervalued after recent price drop

Now 21% undervalued after recent price drop

A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)

Second quarter 2022 earnings released: EPS: kr0.005 (vs kr0.18 in 2Q 2021)

Vistin Pharma ASA Approves Dividend for 2021

Less than half of directors are independent

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Vistin Pharma ASA Announces Executive Changes

Third quarter 2021 earnings released: EPS kr0.021 (vs kr0.10 in 3Q 2020)

Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)

Second quarter 2021 earnings released: EPS kr0.18 (vs kr0.47 in 2Q 2020)

Insider recently sold kr340k worth of stock

Upcoming dividend of kr0.50 per share

Vistin Pharma ASA Announces Dividend, Payable on 3 June 2021

First quarter 2021 earnings released

New 90-day high: kr27.00

Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First

Full year 2020 earnings released: kr2.19 loss per share (vs kr1.49 profit in FY 2019)

We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate

New 90-day high: kr21.70

Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?

The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It

New 90-day high: kr18.80

Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?

Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?

Third quarter earnings released

First half earnings released

Chief Executive Officer recently sold kr1.6m worth of stock

New 90-day high - kr17.95

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane